Retraction: Prognostic and Predictive Value of Carcinoembryonic Antigen and Cytokeratin-19 Fragments Levels in Advanced Non-Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib. Yonsei Med J 2012;53:931-9.

Jung, Minkyu; Kim, Se Hyun; Hong, Soojung; Kang, Young Ae; Kim, Se Kyu; Chang, Joon; Rha, Sun Young; Kim, Joo Hang; Kim, Dae Joon; Cho, Byoung Chul

Yonsei Med J. 2013 Jan;54(1):269-269. 10.3349/ymj.2013.54.1.269.

Retraction: Prognostic and Predictive Value of Carcinoembryonic Antigen and Cytokeratin-19 Fragments Levels in Advanced Non-Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib. Yonsei Med J 2012;53:931-9.

Affiliations

¹Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
²Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
³Division of Pulmonology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
⁴Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine, Seoul, Korea.

KMID: 1776951
DOI: http://doi.org/10.3349/ymj.2013.54.1.269

Abstract

No abstract available.

Reference

1. Jung M, Kim SH, Lee YJ, Hong S, Kang YA, Kim SK, et al. Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. Exp Ther Med. 2011. 2:685–693.
Article

2. Jung M, Kim SH, Hong S, Kang YA, Kim SK, Chang J, et al. Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. Yonsei Med J. 2012. 53:931–939.
Article

Retraction: Prognostic and Predictive Value of Carcinoembryonic Antigen and Cytokeratin-19 Fragments Levels in Advanced Non-Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib. Yonsei Med J 2012;53:931-9.

Abstract

Reference

Cited

Save citations to file

Email citations